Pharmacy services

Tender description

Framework agreement for the provision of homecare medicines services specifically to members of East of England NHS Collaborative Procurement Hub's Pharmacy Procurement Model and members of NHS Commercial Solutions. The framework is broken into 4 lots which will cover the provision of: — Low-tech Homecare medicines services; — Mid-tech Homecare Medicines Services; — High-tech Homecare Medicines Services for Antibiotic Products; — High-tech Homecare Medicines Services. Services are to be provided in line with the Royal Pharmaceutical Society Professional Standards for Homecare. Estimated cost excluding VAT: Range between 75 000 000 and 200 000 000. This Framework Agreement will be accessible to all partly or wholly publicly funded bodies in the United Kingdom. This lot captures low-tech homecare medicines services. This includes, but is not limited to, provision of homecare services for the following areas: — HIV, — Hepatitis, — Oral Chemotherapy, — Immunosuppression, — Erythropoetin Stimulating Agents (ESAs), — Oral and Inhaled Antibiotic Products, — Self-injectable Methotrexate, — Self-Injectable Biologic Products for Rheumatology, Dermatology, Gastroenterology and Neurology Indications, — Other Products requiring low-tech service. Low-tech homecare medicines services will be as defined in the ITT documents which closely aligns to the definitions detailed in the Royal Pharmaceutical Society Professional Standards for Homecare. In brief this can be categorised as dispense and deliver of products for self-administration including, where appropriate, supply of sharps bin and associated waste collection services. This Framework Agreement will include, and be for the benefit of publically funded (both wholly and partially funded) entities in the United Kingdom, including Northern Ireland, Scotland, Wales and England. This will include, but is not limited to: Acute, Ambulance, Mental Health, Clinical Commissioning Groups, Health and Care Trusts, Area Teams, Local Authorities and Special Health Authorities, HSC in Northern Ireland, NHS Scotland and NHS Wales, including any successor or emerging organisations, which will include but is not limited to the emerging landscape of combined health and social care commissioners and providers. Please follow the links below to identify specific organisations: — NHS trusts: http://www.nhs.uk/ServiceDirectories/Pages/AcuteTrustListing.aspx — Clinical Commissioning Groups: http://www.nhs.uk/ServiceDirectories/Pages/CCGListing.aspx — Area Teams: http://www.nhs.uk/ServiceDirectories/Pages/AreaTeamListing.aspx — Local Authorities: https://www.lgbce.org.uk/records-and-resources/local-authorities-in-england — Special health authorities: http://www.nhs.uk/ServiceDirectories/Pages/SpecialHealthAuthorityListing.aspx — HSC in Northern Ireland: http://online.hscni.net/other-hsc-organisations — NHS Scotland: http://www.scot.nhs.uk/organisations/ — NHS Wales: http://www.wales.nhs.uk/ourservices/directory This lot captures mid-tech homecare medicines services. This includes, but is not limited to, provision of homecare services for the following areas: — Hepatitis, — Oral Chemotherapy, — Self-injectable Methotrexate, — Erythropoetin Stimulating Agents (ESAs), — Self-Injectable Biologic Products for Rheumatology, Dermatology, Gastroenterology and Neurology Indications, — Other Products requiring mid-tech service. Mid-tech homecare medicines services will be as defined in the ITT documents which closely aligns to the definitions detailed in the Royal Pharmaceutical Society Professional Standards for Homecare. In brief this can be categorised as dispense and deliver of products for self-administration including, where appropriate, supply of sharps bin and associated waste collection services as well as provision of initial patient training / competency assessment or supply of equipment e.g. refrigerator where required. This Framework Agreement will include, and be for the benefit of publicly funded (both wholly and partially funded) entities in the United Kingdom, including Northern Ireland, Scotland, Wales and England. This will include, but is not limited to: Acute, Ambulance, Mental Health, Clinical Commissioning Groups, Health and Care Trusts, Area Teams, Local Authorities and Special Health Authorities, HSC in Northern Ireland, NHS Scotland and NHS Wales, including any successor or emerging organisations, which will include but is not limited to the emerging landscape of combined health and social care commissioners and providers. Please follow the links below to identify specific organisations: — NHS trusts: http://www.nhs.uk/ServiceDirectories/Pages/AcuteTrustListing.aspx — Clinical Commissioning Groups: http://www.nhs.uk/ServiceDirectories/Pages/CCGListing.aspx — Area Teams: http://www.nhs.uk/ServiceDirectories/Pages/AreaTeamListing.aspx — Local Authorities: https://www.lgbce.org.uk/records-and-resources/local-authorities-in-england — Special health authorities: http://www.nhs.uk/ServiceDirectories/Pages/SpecialHealthAuthorityListing.aspx — HSC in Northern Ireland: http://online.hscni.net/other-hsc-organisations — NHS Scotland: http://www.scot.nhs.uk/organisations/ — NHS Wales: http://www.wales.nhs.uk/ourservices/directory This lot capture high-tech homecare medicines services for antibiotic products. This lot includes application to, but is not limited to, the following indications and services: — Compounded injectable antibiotic products for cystic fibrosis requiring high-tech homecare service activities, — Compounded injectable antibiotic products for other therapeutic indications, — Outpatient Parenteral Antibiotic Therapy (OPAT) / Early discharge, — Admission avoidance, — Supplementary oral or uncompounded antibiotic products. The scope of this Lot is to reflect the current and future requirements of the Participating Authorities and includes the incorporation of new developments in the field which offer benefits to both patient experience and product / service costs. Such developments include, but are not limited to new antibiotic products brought to market, extended stability data and continuous infusions. This Framework Agreement will include, and be for the benefit of publically funded (both wholly and partially funded) entities in the United Kingdom, including Northern Ireland, Scotland, Wales and England. This will include, but is not limited to: Acute, Ambulance, Mental Health, Clinical Commissioning Groups, Health and Care Trusts, Area Teams, Local Authorities and Special Health Authorities, HSC in Northern Ireland, NHS Scotland and NHS Wales, including any successor or emerging organisations, which will include but is not limited to the emerging landscape of combined health and social care commissioners and providers. Please follow the links below to identify specific organisations: — NHS trusts: http://www.nhs.uk/ServiceDirectories/Pages/AcuteTrustListing.aspx — Clinical Commissioning Groups: http://www.nhs.uk/ServiceDirectories/Pages/CCGListing.aspx — Area Teams: http://www.nhs.uk/ServiceDirectories/Pages/AreaTeamListing.aspx — Local Authorities: https://www.lgbce.org.uk/records-and-resources/local-authorities-in-england — Special health authorities: http://www.nhs.uk/ServiceDirectories/Pages/SpecialHealthAuthorityListing.aspx — HSC in Northern Ireland: http://online.hscni.net/other-hsc-organisations — NHS Scotland: http://www.scot.nhs.uk/organisations/ — NHS Wales: http://www.wales.nhs.uk/ourservices/directory This lot, Lot 4 (High-tech homecare medicines services), of the East of England NHS Collaborative Procurement Hub framework agreement for the provision of homecare medicines services captures high-tech homecare services, as defined in the core specification. Services procured under this lot will typically be, but are not limited to: — Services where nurse administration is required to be undertaken by the Contractor and/or — Services which include provision of aseptic compounded of products. This lot is for further competition only and provides a framework for Purchasing Authorities to establish bespoke high-tech homecare services. This Framework Agreement will include, and be for the benefit of publicly funded (both wholly and partially funded) entities in the United Kingdom, including Northern Ireland, Scotland, Wales and England. This will include, but is not limited to: Acute, Ambulance, Mental Health, Clinical Commissioning Groups, Health and Care Trusts, Area Teams, Local Authorities and Special Health Authorities, HSC in Northern Ireland, NHS Scotland and NHS Wales, including any successor or emerging organisations, which will include but is not limited to the emerging landscape of combined health and social care commissioners and providers. Please follow the links below to identify specific organisations: — NHS trusts: http://www.nhs.uk/ServiceDirectories/Pages/AcuteTrustListing.aspx — Clinical Commissioning Groups: http://www.nhs.uk/ServiceDirectories/Pages/CCGListing.aspx — Area Teams: http://www.nhs.uk/ServiceDirectories/Pages/AreaTeamListing.aspx — Local Authorities: https://www.lgbce.org.uk/records-and-resources/local-authorities-in-england — Special health authorities: http://www.nhs.uk/ServiceDirectories/Pages/SpecialHealthAuthorityListing.aspx — HSC in Northern Ireland: http://online.hscni.net/other-hsc-organisations — NHS Scotland: http://www.scot.nhs.uk/organisations/ — NHS Wales: http://www.wales.nhs.uk/ourservices/directory